ImPact Biotech is focused on the development and launch of Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, a targeted treatment for selective tumor ablation. Padeliporfin VTP therapy is a novel Oncology technology platform that comprises the intravenous delivery of an inactive drug, Padeliporfin, which is then precisely activated only in the tumor micro-environment by non-thermal laser light delivered via optical fiber(s). This results in the immediate occlusion of the tumor blood supply followed by self-propagating immunogenic cell death and immune activation with minimal effect on surrounding healthy tissues. ImPact Biotech holds exclusive rights from the Weizmann Institute of Science (WIS, Israel) and Memorial Sloan Kettering Cancer Center (MSKCC, New York), to develop and commercialize drugs and related technologies used in VTP.